{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "LY3298176",
        "type": {
          "id": "fd547074-53dc-404c-baa3-41358244d89a",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "0a8448ef-f008-4e10-84d0-f8708a660839",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "A 39-amino acid synthetic peptide with agonist activity at both the GIP and GLP-1 receptors, administered once weekly.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Insulin Glargine",
        "type": {
          "id": "634afc31-9c24-4964-ad28-5a1dba213b41",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "55f4914f-bb53-4649-9253-5b4215a954b0",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Basal insulin used as an active comparator, titrated following a treat-to-target algorithm.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Metformin",
        "type": {
          "id": "a5fe2da0-b0a0-4320-874b-fdac47e6e8c9",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "fd6ea1aa-47f5-499d-a126-d69ab0020401",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral antihyperglycemic medication; patients must be on a stable dose for at least 90 days prior to screening.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "SGLT-2 inhibitors",
        "type": {
          "id": "db64f6cd-3dfb-4121-bd7e-86fc6b4b9017",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "e0ba0552-b3a5-4f01-b2c6-aa672d35c6c6",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Sodium-glucose co-transporter-2 inhibitors; oral antihyperglycemic medication.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Sulfonylureas",
        "type": {
          "id": "a48ccdd5-858b-42cd-aadb-86f5c0c788a2",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "14430004-c074-4519-a30f-7c06b90b9efa",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral antihyperglycemic medication."
      },
      {
        "id": "int_6",
        "name": "GLP-1 receptor agonists",
        "type": {
          "id": "75503f8b-7f5a-4dff-877e-b5f321976349",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "2bd27f4f-00ea-422d-ac9f-912298f25c96",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medication during the study."
      },
      {
        "id": "int_7",
        "name": "DPP-4 inhibitors",
        "type": {
          "id": "655068fc-6ef1-48ea-9961-b5628a044cc3",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "d7af580b-89cd-4576-947a-072b9987f2ad",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medication during the study."
      },
      {
        "id": "int_8",
        "name": "Amylin analogs",
        "type": {
          "id": "be9b08a6-98d0-4d22-bb24-db70149e23f5",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "ae2020a4-58e6-4dad-b995-26679fdbdec8",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medication during the study."
      },
      {
        "id": "int_9",
        "name": "Weight loss medications",
        "type": {
          "id": "74c499e6-5e86-4a74-9b9e-aa625997e220",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "d860a4fe-c6f8-4003-88f7-fcba2f874bda",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medications including Saxenda, Xenical, Meridia, etc., within 3 months prior to screening."
      },
      {
        "id": "int_10",
        "name": "Paracetamol/aspirin",
        "type": {
          "id": "58c77ac3-71b0-4c58-9b34-1094e4a98008",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "b5688b14-2f0c-4beb-a7dc-8cdcb4ad6c14",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted over-the-counter drugs for symptomatic relief."
      },
      {
        "id": "int_11",
        "name": "Rescue therapy",
        "type": {
          "id": "72d55b86-9dbf-4c1d-a2bc-4da10f55a2ba",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "15a29aff-6655-4a3c-aee8-8ac37cef0296",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "New glucose-lowering intervention for patients with severe, persistent hyperglycemia."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "LY3298176 prefilled syringe",
        "administrableDoseForm": {
          "id": "8ef6d9a4-a7e1-465a-b5f1-ba0d294e718a",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "b38a90e0-4316-4c50-baf2-60eca06077c8",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "55a5f8db-7edf-4579-aeb6-6a0c177a3ddc",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "id": "prod_2",
        "name": "Insulin glargine prefilled pen",
        "administrableDoseForm": {
          "id": "bc592b69-9c95-495c-919c-0c15b4a3b3d7",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "65897f75-4840-4b77-a2ad-06f2b2a1e5ee",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "3ce2a48f-8d6a-4a65-a3de-062462baf6f7",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "100 units/mL (implied by standard pen)",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Marketed product (e.g., Basaglar)"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "LY3298176 5 mg regimen",
        "instanceType": "Administration",
        "dose": "5 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Up to 104 weeks (titration starts at 2.5 mg for 4 weeks)"
      },
      {
        "id": "admin_2",
        "name": "LY3298176 10 mg regimen",
        "instanceType": "Administration",
        "dose": "10 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
      },
      {
        "id": "admin_3",
        "name": "LY3298176 15 mg regimen",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
      },
      {
        "id": "admin_4",
        "name": "Insulin glargine titration",
        "instanceType": "Administration",
        "dose": "Starting 10 IU/day, adjusted based on FBG",
        "doseFrequency": "once daily",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Up to 104 weeks"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "LY3298176",
        "instanceType": "Substance",
        "description": "GIP and GLP-1 receptor agonist; tirzepatide"
      },
      {
        "id": "sub_2",
        "name": "Insulin glargine",
        "instanceType": "Substance",
        "description": "Long-acting basal insulin analogue"
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "Investigational prefilled syringe",
        "instanceType": "MedicalDevice",
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "id": "dev_2",
        "name": "Marketed prefilled pen",
        "instanceType": "MedicalDevice",
        "manufacturer": "Eli Lilly and Company (Basaglar)"
      },
      {
        "id": "dev_3",
        "name": "Blood glucose meter",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      }
    ],
    "summary": {
      "interventionCount": 11,
      "productCount": 2,
      "deviceCount": 3
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "LY3298176",
        "role": "Investigational Product",
        "description": "A 39-amino acid synthetic peptide with agonist activity at both the GIP and GLP-1 receptors, administered once weekly."
      },
      {
        "name": "Insulin Glargine",
        "role": "Comparator",
        "description": "Basal insulin used as an active comparator, titrated following a treat-to-target algorithm."
      },
      {
        "name": "Metformin",
        "role": "Background Therapy",
        "description": "Oral antihyperglycemic medication; patients must be on a stable dose for at least 90 days prior to screening."
      },
      {
        "name": "SGLT-2 inhibitors",
        "role": "Background Therapy",
        "description": "Sodium-glucose co-transporter-2 inhibitors; oral antihyperglycemic medication."
      },
      {
        "name": "Sulfonylureas",
        "role": "Background Therapy",
        "description": "Oral antihyperglycemic medication."
      },
      {
        "name": "GLP-1 receptor agonists",
        "role": "Concomitant Medication",
        "description": "Prohibited medication during the study."
      },
      {
        "name": "DPP-4 inhibitors",
        "role": "Concomitant Medication",
        "description": "Prohibited medication during the study."
      },
      {
        "name": "Amylin analogs",
        "role": "Concomitant Medication",
        "description": "Prohibited medication during the study."
      },
      {
        "name": "Weight loss medications",
        "role": "Concomitant Medication",
        "description": "Prohibited medications including Saxenda, Xenical, Meridia, etc., within 3 months prior to screening."
      },
      {
        "name": "Paracetamol/aspirin",
        "role": "Concomitant Medication",
        "description": "Permitted over-the-counter drugs for symptomatic relief."
      },
      {
        "name": "Rescue therapy",
        "role": "Rescue Medication",
        "description": "New glucose-lowering intervention for patients with severe, persistent hyperglycemia."
      }
    ],
    "products": [
      {
        "name": "LY3298176 prefilled syringe",
        "doseForm": "Injection",
        "strength": "2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg",
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "name": "Insulin glargine prefilled pen",
        "doseForm": "Injection",
        "strength": "100 units/mL (implied by standard pen)",
        "manufacturer": "Marketed product (e.g., Basaglar)"
      }
    ],
    "substances": [
      {
        "name": "LY3298176",
        "description": "GIP and GLP-1 receptor agonist; tirzepatide"
      },
      {
        "name": "Insulin glargine",
        "description": "Long-acting basal insulin analogue"
      }
    ],
    "administrations": [
      {
        "name": "LY3298176 5 mg regimen",
        "dose": "5 mg",
        "frequency": "once weekly",
        "route": "Subcutaneous",
        "duration": "Up to 104 weeks (titration starts at 2.5 mg for 4 weeks)"
      },
      {
        "name": "LY3298176 10 mg regimen",
        "dose": "10 mg",
        "frequency": "once weekly",
        "route": "Subcutaneous",
        "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
      },
      {
        "name": "LY3298176 15 mg regimen",
        "dose": "15 mg",
        "frequency": "once weekly",
        "route": "Subcutaneous",
        "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
      },
      {
        "name": "Insulin glargine titration",
        "dose": "Starting 10 IU/day, adjusted based on FBG",
        "frequency": "once daily",
        "route": "Subcutaneous",
        "duration": "Up to 104 weeks"
      }
    ],
    "devices": [
      {
        "name": "Investigational prefilled syringe",
        "manufacturer": "Eli Lilly and Company",
        "purpose": "Administration of LY3298176"
      },
      {
        "name": "Marketed prefilled pen",
        "manufacturer": "Eli Lilly and Company (Basaglar)",
        "purpose": "Administration of Insulin Glargine"
      },
      {
        "name": "Blood glucose meter",
        "manufacturer": "Not specified",
        "purpose": "Self-monitoring of blood glucose (SMBG)"
      }
    ]
  }
}